Investor Presentaiton
Strong business momentum
Diversified portfolio growth
Efficient compounding engine
Sustainable long-term growth
What does $1bn of investment mean for future cash receipts?
Representative annual Adjusted Cash Receipts (1,2) ("top-line") from $1bn of investment - based on blend of historical acquisitions
$300m
Period of accelerated growth
during product launch
Period of reduced growth in latter-
half of decade post product launch
$200m
$100m
$160-180m
Often significant residual
"tail" beyond 10 years
$160-200m
$0m
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
20
Years Post Acquisition
1. See slide 114 for definitions and factors that may impact the achievement of our growth outlook.
ROYALTY PHARMA
100
2. Representative cash receipts based on blended average of actual and projected returns for approved and development-stage transactions over the last five years under a range of scenariosView entire presentation